Atlanta, GA, September 5, 2002 -- MDdatacor, inc., a medical informatics company that identifies patient populations for clinical trials and approved therapies, today announced it has signed an agreement with the Linked Urology Research Network (LURN), a network of seven research-oriented private urology practices consisting of 104 urologists. Terms of the agreement call for LURN network practices to adopt MDdatacor's MDinsight™ informatics solution to assist them with clinical trial patient recruitment and for LURN to assist MDdatacor in its industry sales initiatives to pharmaceutical and medical device companies.

"We are very pleased to reach an agreement with such a preeminent group of urology practices," commented Blake Whitney, MDdatacor chairman, president and chief executive officer. "This agreement confirms the value of our informatics solution to research-oriented specialty physician groups and will greatly expand our industry marketing efforts."

Physician practices provide MDdatacor with electronic copies of patient chart information, such as transcribed progress notes, lab results and demographic information. MDdatacor uses a patent-pending technology to convert this information into a searchable clinical database. Within each individual practice, physicians can use this online database to help identify patients who may need additional medical follow-up. It also allows physicians to quickly determine which subjects may qualify for a clinical trial or a new medically-indicated drug or device therapy. MDdatacor's industry solutions help pharmaceutical firms and medical device manufacturers accelerate clinical trial screening and enrollment processes, reducing the time and cost of new product and drug development.

"MDdatacor has a unique solution that we believe will help us accelerate our practices' clinical trial enrollment. We are pleased with the firm's attention to the HIPAA privacy and security regulations and the fact they share our concern for the confidentiality of patient medical information," said Margaret Fay, Ph.D. chief executive officer of LURN. "Our superior trial enrollment experience gives us unique access to and credibility with drug and device companies who are not currently aware of MDdatacor. We look forward to leveraging these relationships to the benefit of Sponsors, LURN, our patients and MDdatacor."